briakinumab: Clinical Trials

9 trials of briakinumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 terminated, 1 withdrawn. 5 Phase 3, 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5
Phase 13Completed 2, Withdrawn 1
Phase 21Terminated 1

Follow briakinumab: new trials by email Literature Review of briakinumab trials Research Report on briakinumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
briakinumab - Moderate to Severe Plaque Psoriasis
Phase 1WithdrawnAbbott122011-04-012011-10-21
Phase 1 BA Study, Single Center With Healthy Volunteers
ABT-874 - Healthy
Phase 1CompletedAbbott752009-01-012010-11-08
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
ABT-874, etanercept, placebo - Moderate to Severe Plaque Psoriasis
Phase 3CompletedAbbVie (prior sponsor, Abbott)3502008-07-012013-01-18
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
ABT-874, etanercept, placebo - Plaque Psoriasis
Phase 3CompletedAbbVie (prior sponsor, Abbott)3472008-05-012013-01-21
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
ABT-874, Methotrexate - Psoriasis
Phase 3CompletedAbbVie (prior sponsor, Abbott)3172008-04-012013-01-29
Open Label Continuation Study in Moderate to Severe Psoriasis
ABT-874 - Moderate to Severe Plaque Psoriasis
Phase 3CompletedAbbVie (prior sponsor, Abbott)23012008-02-012013-01-30
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
Placebo, ABT-874 - Crohn's Disease
Phase 2TerminatedAbbott2462007-11-012011-08-23
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo, ABT-874 - Plaque Psoriasis
Phase 3CompletedAbbVie (prior sponsor, Abbott)14652007-11-012013-02-08
Monoclonal Antibody Treatment of Crohn's Disease
J695 - Crohn's Disease
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)402000-12-012008-03-04

Conditions studied

Crohn Disease (2)  ·  Psoriasis (1)

Sponsors

AbbVie (prior sponsor, Abbott) (5)  ·  Abbott (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

United States (7)  ·  Canada (4)  ·  Austria (3)  ·  Belgium (3)  ·  Denmark (3)  ·  Finland (2)  ·  France (2)  ·  Germany (2)  ·  Greece (2)  ·  Italy (2)  ·  Spain (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  Australia (1)

Top investigators

Martin Kaul, MD (5)  ·  David A Williams, MD (1)  ·  Joaquin Valdes, MD (1)  ·  Roberto Carcereri, MD (1)

Results publications

PMID 21574983, PMID 21574984, PMID 22029980, PMID 22169986

NIH funding

2008 (1)